NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product rexlemestrocel-L in patients with chronic low back pain (CLBP) due to inflammatory degenerative disc disease of…
Thu, 19 Sep 2024 00:15:00 GMT HEALWELL’s subsidiary, BioPharma Services, is expanding into late-stage patient trials through the integration of Canadian Phase Onward, a dedicated clinical research site built within the framework ...
Mon, 16 Sep 2024 05:00:00 GMT Massive Bio, a global leader in artificial intelligence (AI) for cancer clinical trial enrollment, has announced the launch of Patient Connect, an innovative and free portal designed to help cancer ...
Mon, 09 Sep 2024 05:59:00 GMT SAB-142 has completed Phase 1 enrollment of all planned cohorts in healthy volunteers and is progressing to enroll patients with type 1 diabetes ...
Mon, 09 Sep 2024 04:30:00 GMT CRANBURY, N.J. , Sept. 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
Thu, 08 Aug 2024 03:59:00 GMT Completed divestiture of China operations Uliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody) Clinical collaboration and supply agreement with Bri ...
